Table 3.

COVID-19-related mortality after the first and second doses in people vaccinated with BNT162b2 mRNA.

First author	Vaccine type	Country	Type of study	Group of study	SARS-COV 2 incidence
					Partial vaccinated		Unvaccinated		Rate ratio*	Full vaccinated		Unvaccinated		Rate ratio*
					Death	Pearson day	Death	Pearson day		Death	Pearson day	Death	Pearson day
Noa Dagan (33)	BNT162b2 mRNA	Israel	Prospective cohort study	Age of ≥16 and older	2	2,64,538	6	2,64,479	0.333	9	4,322	32	4,316	0.281
Eric J. Haas (18)	BNT162b2 mRNA	Israel	Prospective cohort study	Age of 16 and older.	-	-	-	-	-	138	20,18,82,183	715	12,00,76,136	0.115
Arjun Puranik (40)	BNT162b2 mRNA	USA	Retrospective cohort	Aged ≥18 years	0	1,80,814	0	1,80,819	-	0	23,33,860	4	25,37,030	0
Carmen Cabezas (42)	BNT162b2 mRNA	Catalonia	Prospective cohort study	Healthcare workers	153	30,30,779	272	6,39,181	0.119	33	27,45,713	272	6,39,181	0.028
Aharona Freedman (43)	BNT162b2 mRNA	Israel	Retrospective cohort	Aged ≥16 years	178	1,42,89,253	819	11,97,01,675	1.821	61	1,40,60,250	567	8,95,35,711	0.685
Hanne-Dorthe Emborg (45)	BNT162b2 mRNA	Denmark	Prospective cohort study	-	203	45,51,842	445	5,59,10,554	5.603	25	1,37,35,570	445	5,59,10,554	0.229
Arjun Puranik (40)	mRNA-1273	USA	Retrospective cohort	Aged ≥18 years	0	1,80,951	0	1,80,819	-	0	22,15,773	4	25,37,030	0
Subhadeep Ghosh (48)	ChAdOx1	India	Prospective cohort study	Healthcare workers	16	4,96,53,918	37	10,65,94,492	0.928	7	5,86,74,639	37	10,65,94,492	0.344
Baltazar Nunes (71)	Combination†	Portugal	Prospective cohort study	Aged ≥65 years	11	2,15,60,915	90	5,29,45,805	0.3	14	4,88,53,060	90	5,29,45,805	0.169

^*Rate Ratio computed.

^†BNT162b2 mRNA and mRNA-1273 and ChAdOx1.